Immunopathogenesis


Since the onset of the COVID-19 pandemic in the fall of 2019 over 4 million people have been infected and over 280,000 have died (1). Information about the SARS-CoV2 virus is evolving rapidly. At this time there are no interventions proven to be effective for cases infected with SARS-CoV2. Current knowledge about the clinical and laboratory manifestations of COVID-19 infection is reviewed and combined with knowledge about the immunopathogenic mechanisms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV1) and Middle East Respiratory Syndrome (MERS) to formulate theories and suggest possible therapeutic interventions. SARS-CoV2 immunopathogenic mechanisms vary from immunosuppression that initially enables viral escape to a hyperinflammatory immune response. Ultimately therapeutic intervention will be phase dependent.



 


  • Infection
  • Asymptomatic
  • Symptomatic
  • AIDS/Progression of HIV to AIDS

Related Conference of Immunopathogenesis

May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland
October 24-25, 2024

5th International Conference on Immunology And Immunotherapy

Zurich, Switzerland

Immunopathogenesis Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in